QIAGEN Showcases PCR and Sequencing Tools for Cyclospora Detection and Public Health Investigations

QIAstat Dx Rise, operating, touch screen, Lab, Laboratory, open draw, handling, female scientist, woman, QIAGEN employee, Syndromic testing, infectious disease, Chrishanthi Chrissy Lowe, Technical Service Expert

(IN BRIEF) QIAGEN has highlighted its molecular testing portfolio as U.S. health authorities investigate a growing Cyclospora outbreak. More than 1,600 confirmed cases of cyclosporiasis have been reported in the United States since May 2026, with another 7,000 potential cases under review. The company said its FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora cayetanensis in about one hour as part of a 16-target gastrointestinal pathogens panel. QIAGEN also offers research-use tools including a digital PCR assay for the QIAcuity system and the PulseNet-approved QIAseq FX DNA Library Prep Kit for next-generation sequencing workflows. QIAGEN said its technologies can support clinical laboratories, researchers and public health authorities in detecting infections, investigating outbreaks and responding to emerging foodborne disease threats.

(PRESS RELEASE) VENLO, 16-Jul-2026 — /EuropaWire/ — QIAGEN N.V. has highlighted its molecular testing solutions as U.S. health authorities respond to a growing number of cyclosporiasis cases linked to the foodborne parasite Cyclospora cayetanensis.

More than 1,600 confirmed cases of cyclosporiasis have been reported in the United States since May 2026, alongside a further 7,000 potential cases, as authorities investigate multiple outbreaks across the country.

Cyclospora cayetanensis can cause prolonged diarrhoea and other gastrointestinal symptoms. Because the parasite is not detected through routine stool culture, specialised diagnostic methods, including molecular testing, are required to identify infections.

QIAGEN said its Sample to Insight portfolio supports laboratories across several areas of molecular testing, including syndromic diagnostics, digital PCR and next-generation sequencing.

The company’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 includes Cyclospora cayetanensis as a standard target within a 16-target menu covering bacterial, viral and parasitic gastrointestinal pathogens.

The fully integrated syndromic test can deliver results in about one hour, allowing laboratories to test for Cyclospora alongside other common causes of gastrointestinal illness directly from the initial patient sample.

For research use only, QIAGEN also offers a digital PCR Microbial DNA Detection Assay targeting Cyclospora cayetanensis for use with the QIAcuity digital PCR system. The assay supports highly sensitive detection in research and public health applications.

QIAGEN’s sequencing portfolio also includes the PulseNet-approved QIAseq FX DNA Library Prep Kit, which is also for research use only and can be used with any next-generation sequencing platform.

The kit is designed to support shotgun sequencing workflows, which analyse all DNA in a sample to help identify and characterise foodborne pathogens. This supports PulseNet, the U.S. public health laboratory network that detects and investigates foodborne disease outbreaks.

Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN, said the increase in cyclosporiasis cases underlines the importance of rapid and reliable detection.

“The current rise in cyclosporiasis cases highlights the need for rapid, reliable detection to support timely patient care and effective public health action,” said Sood.

He added that QIAGEN is ready to support laboratories and public health authorities worldwide with molecular testing technologies that help detect infections, guide investigations and strengthen responses to emerging disease threats.

QIAGEN said further information about its molecular testing solutions for clinical diagnostics, research and public health laboratories is available through local company representatives and its customer care team.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Media Contact:

John Gilardi
Vice President
Head of Corporate Communications
Global
Germany: +49 2103 29 11711
Mobile: +49 152 018 11711
john.gilardi@qiagen.com

SOURCE: QIAGEN